Endurant Capital Management LP Adaptimmune Therapeutics PLC Transaction History

Endurant Capital Management LP

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$0.9 - $1.51 $755,817 - $1.27 Million	-839,797 Reduced 50.56%	821,038 $755,000
Q1 2023 May 15, 2023	SELL	$1.06 - $2.16 $76,745 - $156,386	-72,401 Reduced 4.18%	1,660,835 $1.81 Million
Q4 2022 Feb 14, 2023	SELL	$1.05 - $2.53 $58,045 - $139,860	-55,281 Reduced 3.09%	1,733,236 $2.53 Million
Q3 2022 Nov 14, 2022	SELL	$1.06 - $2.41 $37,680 - $85,670	-35,548 Reduced 1.95%	1,788,517 $1.92 Million
Q2 2022 Aug 15, 2022	SELL	$1.33 - $2.28 $447,977 - $767,960	-336,825 Reduced 15.59%	1,824,065 $3.1 Million
Q1 2022 May 16, 2022	BUY	$1.73 - $4.06 $2.19 Million - $5.13 Million	1,263,311 Added 140.75%	2,160,890 $4.45 Million
Q4 2021 Feb 14, 2022	SELL	$3.5 - $5.68 $69,681 - $113,083	-19,909 Reduced 2.17%	897,579 $3.37 Million
Q3 2021 Nov 15, 2021	SELL	$3.44 - $6.37 $2.14 Million - $3.96 Million	-621,947 Reduced 40.4%	917,488 $4.74 Million
Q2 2021 Aug 16, 2021	BUY	$3.86 - $5.78 $2.41 Million - $3.61 Million	623,724 Added 68.11%	1,539,435 $6.56 Million
Q1 2021 May 17, 2021	SELL	$4.9 - $6.83 $796,083 - $1.11 Million	-162,466 Reduced 15.07%	915,711 $4.86 Million
Q4 2020 Feb 16, 2021	BUY	$4.0 - $9.2 $2.01 Million - $4.63 Million	503,675 Added 87.67%	1,078,177 $5.81 Million
Q3 2020 Nov 16, 2020	BUY	$7.66 - $10.78 $700,116 - $985,281	91,399 Added 18.92%	574,502 $4.59 Million
Q2 2020 Aug 14, 2020	BUY	$2.58 - $12.1 $834,054 - $3.91 Million	323,277 Added 202.27%	483,103 $4.84 Million
Q1 2020 May 15, 2020	BUY	$1.2 - $4.52 $191,791 - $722,413	159,826 New	159,826 $435,000

152M

78.5K

36.5K

Ticker ADAP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 163,370,000
Market Cap $121M
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...

Get notified when there are updates to the investment portfolio of Endurant Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Endurant Capital Management LP with notifications on news.